Emerging studies suggest Retatrutide , a dual stimulator targeting both GLP-1 and GIP , could provide a notable development for weight management . Early clinical investigations have indicated substantial reductions in abdominal tissue, possibly outperforming existing weight-loss medications . Despite this, more assessment is required to completely